YM060

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Irritable Bowel Syndrome

Conditions

Irritable Bowel Syndrome

Trial Timeline

— → —

NCT ID

NCT00189696

About YM060

YM060 is a phase 3 stage product being developed by Astellas Pharma for Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00189696. Target conditions include Irritable Bowel Syndrome.

What happened to similar drugs?

7 of 20 similar drugs in Irritable Bowel Syndrome were approved

Approved (7) Terminated (1) Active (13)

✅Ramosetron + PlaceboAstellas PharmaApproved

✅duloxetineEli LillyApproved

✅Bacillus clausii + MetronidazoleSanofiApproved

✅Iberogast® and Iberogast® NBayerApproved

✅LinaclotideIronwood PharmaceuticalsApproved

✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00189696	Phase 3	Completed	—	—	Irritable Bowel Syndrome
NCT01736423	Phase 3	Completed	Sep 1, 2012	May 1, 2014	Diarrhea-predominant Irritable Bowel Syndrome
NCT01394653	Phase 1	Completed	Jul 1, 2011	Aug 1, 2011	Healthy
NCT01392794	Phase 1	Completed	Apr 1, 2011	May 1, 2011	Healthy
NCT00189813	Phase 2	Completed	Mar 1, 2005	Dec 1, 2005	Irritable Bowel Syndrome

Competing Products

20 competing products in Irritable Bowel Syndrome

See all competitors

Product	Company	Stage	Hype Score
linaclotide + placebo	Astellas Pharma	Phase 2	35
YM060 + Placebo	Astellas Pharma	Phase 3	40
Ramosetron + Placebo	Astellas Pharma	Approved	43
Ramosetron + Placebo	Astellas Pharma	Approved	43
YM060 + placebo	Astellas Pharma	Phase 2	35
YM060	Astellas Pharma	Phase 3	40
linaclotide + Placebo	Astellas Pharma	Phase 3	40
Ramosetron	Astellas Pharma	Pre-clinical	26
YM060	Astellas Pharma	Phase 2	35
ONO-2952 + Placebo comparator	Ono Pharmaceutical	Phase 2	27
ONO-2952 + ONO-2952 Matching Placebo	Ono Pharmaceutical	Phase 2	35
duloxetine	Eli Lilly	Approved	43
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)	AbbVie	Phase 3	40
25mg Eluxadoline + 100mg Eluxadoline	AbbVie	Phase 3	47
Eluxadoline + Placebo	AbbVie	Phase 2	42
Placebo + Linaclotide	AstraZeneca	Phase 3	40
Tegaserod	Novartis	Pre-clinical	26
DNK333	Novartis	Phase 2	35
SMS995 + Placebo	Novartis	Phase 1	29
DNK333 + Placebo	Novartis	Phase 2	35